A group from University of Oxford, Oxford, UK, etc. has reported on protection from B.1.617.1 and B.1.617.2 by vaccine serum.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218332/
Kappa variant = B.1.617.1 is characterized by two mutations L452R and E484Q in the RBD, and delta variant = B.1.617.2 is characterized by two mutations L452R and T478K in the RBD). The L452R mutation is the common in those variants.
Authors tested neutralization of B.1.617.1 and B.1.617.2 using serum from individuals who had received 2 doses of the BNT162b2 Pfizer-BioNTech or ChAdOx1 nCoV-19 Oxford-AstraZeneca vaccine.
Geometric mean neutralization titers against B.1.617.1 were reduced 2.7-fold (p < 0.0001) relative to the Victoria virus for the Pfizer-BioNTech vaccine serum, and 2.6-fold (p < 0.0001) for the Oxford-AstraZeneca vaccine. The Victoria virus is a Wuhan-related strain isolated early in the pandemic from Australia. For B.1.617.2, titers were reduced 2.5-fold (p < 0.0001) relative to the Victoria virus for the Pfizer-BioNTech vaccine serum and 4.3-fold (p < 0.0001) for the Oxford-AstraZeneca vaccine. Although significant reductions in neutralization titers of sera collected from recipients of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines were observed as such, but make sure that there is no evidence of complete escape from neutralization.